Zoetis Inc.
Zoetis Inc. ZTS Peers
See (ZTS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZTS | $168.68 | +0.05% | 75.1B | 30.28 | $5.57 | +1.10% |
| HLN | $11.11 | +1.60% | 50.2B | 25.83 | $0.43 | +1.51% |
| TAK | $15.00 | -0.20% | 47.2B | 65.22 | $0.23 | +3.94% |
| TEVA | $17.24 | -1.63% | 19.7B | -14.99 | -$1.15 | N/A |
| ITCI | $131.87 | N/A | 14B | -180.64 | -$0.73 | N/A |
| RDY | $15.53 | +5.29% | 12.9B | 19.66 | $0.79 | +0.62% |
| NBIX | $124.61 | +0.07% | 12.3B | 42.24 | $2.95 | N/A |
| CTLT | $63.48 | N/A | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $8.46 | -1.51% | 9.9B | -2.66 | -$3.18 | +5.67% |
| RGC | $617.52 | -2.00% | 8B | -2058.40 | -$0.30 | N/A |
Stock Comparison
ZTS vs HLN Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, HLN has a market cap of 50.2B. Regarding current trading prices, ZTS is priced at $168.68, while HLN trades at $11.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas HLN's P/E ratio is 25.83. In terms of profitability, ZTS's ROE is +0.51%, compared to HLN's ROE of +0.09%. Regarding short-term risk, ZTS is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs TAK Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, TAK has a market cap of 47.2B. Regarding current trading prices, ZTS is priced at $168.68, while TAK trades at $15.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas TAK's P/E ratio is 65.22. In terms of profitability, ZTS's ROE is +0.51%, compared to TAK's ROE of +0.04%. Regarding short-term risk, ZTS is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs TEVA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, TEVA has a market cap of 19.7B. Regarding current trading prices, ZTS is priced at $168.68, while TEVA trades at $17.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas TEVA's P/E ratio is -14.99. In terms of profitability, ZTS's ROE is +0.51%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, ZTS is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ITCI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ZTS is priced at $168.68, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ZTS's ROE is +0.51%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, ZTS is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs RDY Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, RDY has a market cap of 12.9B. Regarding current trading prices, ZTS is priced at $168.68, while RDY trades at $15.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas RDY's P/E ratio is 19.66. In terms of profitability, ZTS's ROE is +0.51%, compared to RDY's ROE of +0.18%. Regarding short-term risk, ZTS is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs NBIX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, NBIX has a market cap of 12.3B. Regarding current trading prices, ZTS is priced at $168.68, while NBIX trades at $124.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas NBIX's P/E ratio is 42.24. In terms of profitability, ZTS's ROE is +0.51%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, ZTS is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs CTLT Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ZTS is priced at $168.68, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ZTS's ROE is +0.51%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, ZTS is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs VTRS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, VTRS has a market cap of 9.9B. Regarding current trading prices, ZTS is priced at $168.68, while VTRS trades at $8.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas VTRS's P/E ratio is -2.66. In terms of profitability, ZTS's ROE is +0.51%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, ZTS is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs RGC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, RGC has a market cap of 8B. Regarding current trading prices, ZTS is priced at $168.68, while RGC trades at $617.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas RGC's P/E ratio is -2058.40. In terms of profitability, ZTS's ROE is +0.51%, compared to RGC's ROE of -0.25%. Regarding short-term risk, ZTS is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ELAN Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ELAN has a market cap of 6.7B. Regarding current trading prices, ZTS is priced at $168.68, while ELAN trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ELAN's P/E ratio is 17.89. In terms of profitability, ZTS's ROE is +0.51%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, ZTS is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs LNTH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, LNTH has a market cap of 5.6B. Regarding current trading prices, ZTS is priced at $168.68, while LNTH trades at $80.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas LNTH's P/E ratio is 22.89. In terms of profitability, ZTS's ROE is +0.51%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ZTS is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PRGO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, PRGO has a market cap of 3.6B. Regarding current trading prices, ZTS is priced at $168.68, while PRGO trades at $25.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas PRGO's P/E ratio is -21.64. In terms of profitability, ZTS's ROE is +0.51%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, ZTS is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs AMRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, AMRX has a market cap of 3.3B. Regarding current trading prices, ZTS is priced at $168.68, while AMRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas AMRX's P/E ratio is -179.25. In terms of profitability, ZTS's ROE is +0.51%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, ZTS is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ALVO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ALVO has a market cap of 3.2B. Regarding current trading prices, ZTS is priced at $168.68, while ALVO trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ALVO's P/E ratio is 28.38. In terms of profitability, ZTS's ROE is +0.51%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, ZTS is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ALVOW Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ALVOW has a market cap of 3.1B. Regarding current trading prices, ZTS is priced at $168.68, while ALVOW trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.51%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, ZTS is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs HCM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, ZTS is priced at $168.68, while HCM trades at $15.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas HCM's P/E ratio is 76.30. In terms of profitability, ZTS's ROE is +0.51%, compared to HCM's ROE of +0.05%. Regarding short-term risk, ZTS is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs BGM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, BGM has a market cap of 2.5B. Regarding current trading prices, ZTS is priced at $168.68, while BGM trades at $12.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas BGM's P/E ratio is -67.55. In terms of profitability, ZTS's ROE is +0.51%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ZTS is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs DCPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ZTS is priced at $168.68, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ZTS's ROE is +0.51%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, ZTS is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs EMBCV Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ZTS is priced at $168.68, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.51%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, ZTS is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SUPN Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, SUPN has a market cap of 1.8B. Regarding current trading prices, ZTS is priced at $168.68, while SUPN trades at $32.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas SUPN's P/E ratio is 29.12. In terms of profitability, ZTS's ROE is +0.51%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, ZTS is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs BHC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, BHC has a market cap of 1.7B. Regarding current trading prices, ZTS is priced at $168.68, while BHC trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas BHC's P/E ratio is -38.54. In terms of profitability, ZTS's ROE is +0.51%, compared to BHC's ROE of +0.05%. Regarding short-term risk, ZTS is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs INDV Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, INDV has a market cap of 1.7B. Regarding current trading prices, ZTS is priced at $168.68, while INDV trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas INDV's P/E ratio is -271.80. In terms of profitability, ZTS's ROE is +0.51%, compared to INDV's ROE of -0.01%. Regarding short-term risk, ZTS is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TARO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ZTS is priced at $168.68, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas TARO's P/E ratio is 30.05. In terms of profitability, ZTS's ROE is +0.51%, compared to TARO's ROE of +0.02%. Regarding short-term risk, ZTS is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs EVO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, EVO has a market cap of 1.4B. Regarding current trading prices, ZTS is priced at $168.68, while EVO trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas EVO's P/E ratio is -6.08. In terms of profitability, ZTS's ROE is +0.51%, compared to EVO's ROE of -0.22%. Regarding short-term risk, ZTS is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ANIP Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ANIP has a market cap of 1.3B. Regarding current trading prices, ZTS is priced at $168.68, while ANIP trades at $59.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ANIP's P/E ratio is -50.70. In terms of profitability, ZTS's ROE is +0.51%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, ZTS is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PCRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, PCRX has a market cap of 1.2B. Regarding current trading prices, ZTS is priced at $168.68, while PCRX trades at $26.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas PCRX's P/E ratio is -11.93. In terms of profitability, ZTS's ROE is +0.51%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, ZTS is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs AMPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, ZTS is priced at $168.68, while AMPH trades at $25.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas AMPH's P/E ratio is 9.25. In terms of profitability, ZTS's ROE is +0.51%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, ZTS is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs DVAX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, ZTS is priced at $168.68, while DVAX trades at $9.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas DVAX's P/E ratio is -19.90. In terms of profitability, ZTS's ROE is +0.51%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ZTS is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs HROW Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, ZTS is priced at $168.68, while HROW trades at $28.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas HROW's P/E ratio is -47.08. In terms of profitability, ZTS's ROE is +0.51%, compared to HROW's ROE of -0.36%. Regarding short-term risk, ZTS is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PAHC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, PAHC has a market cap of 967.5M. Regarding current trading prices, ZTS is priced at $168.68, while PAHC trades at $23.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas PAHC's P/E ratio is 30.60. In terms of profitability, ZTS's ROE is +0.51%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, ZTS is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs COLL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, COLL has a market cap of 947.6M. Regarding current trading prices, ZTS is priced at $168.68, while COLL trades at $29.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas COLL's P/E ratio is 24.16. In terms of profitability, ZTS's ROE is +0.51%, compared to COLL's ROE of +0.19%. Regarding short-term risk, ZTS is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PETQ Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ZTS is priced at $168.68, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ZTS's ROE is +0.51%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, ZTS is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs AVDL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, AVDL has a market cap of 913.2M. Regarding current trading prices, ZTS is priced at $168.68, while AVDL trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas AVDL's P/E ratio is -36.31. In terms of profitability, ZTS's ROE is +0.51%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, ZTS is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs CRON Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, CRON has a market cap of 736.2M. Regarding current trading prices, ZTS is priced at $168.68, while CRON trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas CRON's P/E ratio is 13.64. In terms of profitability, ZTS's ROE is +0.51%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ZTS is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EOLS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, EOLS has a market cap of 627.3M. Regarding current trading prices, ZTS is priced at $168.68, while EOLS trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas EOLS's P/E ratio is -10.93. In terms of profitability, ZTS's ROE is +0.51%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, ZTS is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EMBC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, EMBC has a market cap of 583.3M. Regarding current trading prices, ZTS is priced at $168.68, while EMBC trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas EMBC's P/E ratio is 11.21. In terms of profitability, ZTS's ROE is +0.51%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, ZTS is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs BDSI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ZTS is priced at $168.68, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ZTS's ROE is +0.51%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ZTS is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs SIGA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, SIGA has a market cap of 420.1M. Regarding current trading prices, ZTS is priced at $168.68, while SIGA trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas SIGA's P/E ratio is 8.78. In terms of profitability, ZTS's ROE is +0.51%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, ZTS is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TLRY Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, TLRY has a market cap of 397.2M. Regarding current trading prices, ZTS is priced at $168.68, while TLRY trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas TLRY's P/E ratio is -0.35. In terms of profitability, ZTS's ROE is +0.51%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, ZTS is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs KMDA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, KMDA has a market cap of 389.9M. Regarding current trading prices, ZTS is priced at $168.68, while KMDA trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas KMDA's P/E ratio is 24.21. In terms of profitability, ZTS's ROE is +0.51%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, ZTS is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ORGO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ORGO has a market cap of 365.3M. Regarding current trading prices, ZTS is priced at $168.68, while ORGO trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ORGO's P/E ratio is -18.00. In terms of profitability, ZTS's ROE is +0.51%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, ZTS is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs AQST Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, AQST has a market cap of 354.6M. Regarding current trading prices, ZTS is priced at $168.68, while AQST trades at $3.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas AQST's P/E ratio is -6.16. In terms of profitability, ZTS's ROE is +0.51%, compared to AQST's ROE of +1.07%. Regarding short-term risk, ZTS is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SNDL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, SNDL has a market cap of 330.6M. Regarding current trading prices, ZTS is priced at $168.68, while SNDL trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas SNDL's P/E ratio is -4.28. In terms of profitability, ZTS's ROE is +0.51%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, ZTS is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EBS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, EBS has a market cap of 328.5M. Regarding current trading prices, ZTS is priced at $168.68, while EBS trades at $6.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas EBS's P/E ratio is -2.35. In terms of profitability, ZTS's ROE is +0.51%, compared to EBS's ROE of -0.27%. Regarding short-term risk, ZTS is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TKNO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, TKNO has a market cap of 308.6M. Regarding current trading prices, ZTS is priced at $168.68, while TKNO trades at $5.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas TKNO's P/E ratio is -12.55. In terms of profitability, ZTS's ROE is +0.51%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, ZTS is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ALIM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ZTS is priced at $168.68, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ZTS's ROE is +0.51%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, ZTS is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs ZYBT Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ZYBT has a market cap of 298.1M. Regarding current trading prices, ZTS is priced at $168.68, while ZYBT trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ZYBT's P/E ratio is 104.83. In terms of profitability, ZTS's ROE is +0.51%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, ZTS is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ACB Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ACB has a market cap of 296.6M. Regarding current trading prices, ZTS is priced at $168.68, while ACB trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ACB's P/E ratio is 27.03. In terms of profitability, ZTS's ROE is +0.51%, compared to ACB's ROE of +0.02%. Regarding short-term risk, ZTS is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs CGC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, CGC has a market cap of 284.5M. Regarding current trading prices, ZTS is priced at $168.68, while CGC trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas CGC's P/E ratio is -0.33. In terms of profitability, ZTS's ROE is +0.51%, compared to CGC's ROE of -1.13%. Regarding short-term risk, ZTS is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs LNDC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ZTS is priced at $168.68, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ZTS's ROE is +0.51%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, ZTS is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs LFCR Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, LFCR has a market cap of 250.5M. Regarding current trading prices, ZTS is priced at $168.68, while LFCR trades at $6.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas LFCR's P/E ratio is -4.60. In terms of profitability, ZTS's ROE is +0.51%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, ZTS is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TYHT Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ZTS is priced at $168.68, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ZTS's ROE is +0.51%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, ZTS is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ESPR Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ESPR has a market cap of 228.9M. Regarding current trading prices, ZTS is priced at $168.68, while ESPR trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ESPR's P/E ratio is -1.36. In terms of profitability, ZTS's ROE is +0.51%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, ZTS is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs REPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ZTS is priced at $168.68, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas REPH's P/E ratio is -8.04. In terms of profitability, ZTS's ROE is +0.51%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ZTS is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs DERM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, DERM has a market cap of 176.7M. Regarding current trading prices, ZTS is priced at $168.68, while DERM trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas DERM's P/E ratio is -20.50. In terms of profitability, ZTS's ROE is +0.51%, compared to DERM's ROE of -0.52%. Regarding short-term risk, ZTS is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs OGI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, OGI has a market cap of 175.4M. Regarding current trading prices, ZTS is priced at $168.68, while OGI trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas OGI's P/E ratio is 10.08. In terms of profitability, ZTS's ROE is +0.51%, compared to OGI's ROE of +0.05%. Regarding short-term risk, ZTS is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs BIOA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, BIOA has a market cap of 159.2M. Regarding current trading prices, ZTS is priced at $168.68, while BIOA trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas BIOA's P/E ratio is -2.24. In terms of profitability, ZTS's ROE is +0.51%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, ZTS is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs THTX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, THTX has a market cap of 120.9M. Regarding current trading prices, ZTS is priced at $168.68, while THTX trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas THTX's P/E ratio is -37.57. In terms of profitability, ZTS's ROE is +0.51%, compared to THTX's ROE of +0.16%. Regarding short-term risk, ZTS is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SCTL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ZTS is priced at $168.68, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ZTS's ROE is +0.51%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ZTS is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs CRDL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, CRDL has a market cap of 114.1M. Regarding current trading prices, ZTS is priced at $168.68, while CRDL trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas CRDL's P/E ratio is -4.06. In terms of profitability, ZTS's ROE is +0.51%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, ZTS is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PROC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, PROC has a market cap of 114M. Regarding current trading prices, ZTS is priced at $168.68, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas PROC's P/E ratio is 1.53. In terms of profitability, ZTS's ROE is +0.51%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ZTS is less volatile compared to PROC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs OPTN Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ZTS is priced at $168.68, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ZTS's ROE is +0.51%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, ZTS is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs ZOM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ZTS is priced at $168.68, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ZTS's ROE is +0.51%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, ZTS is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs IRWD Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, IRWD has a market cap of 92.4M. Regarding current trading prices, ZTS is priced at $168.68, while IRWD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas IRWD's P/E ratio is -3.01. In terms of profitability, ZTS's ROE is +0.51%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, ZTS is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs GRVI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ZTS is priced at $168.68, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ZTS's ROE is +0.51%, compared to GRVI's ROE of -5.25%. Regarding short-term risk, ZTS is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs CPIX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, CPIX has a market cap of 80.7M. Regarding current trading prices, ZTS is priced at $168.68, while CPIX trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas CPIX's P/E ratio is -22.47. In terms of profitability, ZTS's ROE is +0.51%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, ZTS is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ZYNE Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ZTS is priced at $168.68, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ZTS's ROE is +0.51%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ZTS is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs INCR Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, INCR has a market cap of 69.3M. Regarding current trading prices, ZTS is priced at $168.68, while INCR trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas INCR's P/E ratio is -3.50. In terms of profitability, ZTS's ROE is +0.51%, compared to INCR's ROE of -0.07%. Regarding short-term risk, ZTS is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SSIC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ZTS is priced at $168.68, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ZTS's ROE is +0.51%, compared to SSIC's ROE of +0.03%. Regarding short-term risk, ZTS is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ASRT Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ASRT has a market cap of 62.4M. Regarding current trading prices, ZTS is priced at $168.68, while ASRT trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ASRT's P/E ratio is -2.04. In terms of profitability, ZTS's ROE is +0.51%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, ZTS is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs VLNS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ZTS is priced at $168.68, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ZTS's ROE is +0.51%, compared to VLNS's ROE of N/A. Regarding short-term risk, ZTS is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs JUPW Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ZTS is priced at $168.68, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ZTS's ROE is +0.51%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, ZTS is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs QNTM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, QNTM has a market cap of 40M. Regarding current trading prices, ZTS is priced at $168.68, while QNTM trades at $13.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas QNTM's P/E ratio is -1.04. In terms of profitability, ZTS's ROE is +0.51%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, ZTS is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs QLI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ZTS is priced at $168.68, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas QLI's P/E ratio is -4.92. In terms of profitability, ZTS's ROE is +0.51%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ZTS is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs SXTC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, SXTC has a market cap of 34.9M. Regarding current trading prices, ZTS is priced at $168.68, while SXTC trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas SXTC's P/E ratio is 0.01. In terms of profitability, ZTS's ROE is +0.51%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, ZTS is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SCYX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, SCYX has a market cap of 34.6M. Regarding current trading prices, ZTS is priced at $168.68, while SCYX trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas SCYX's P/E ratio is -1.58. In terms of profitability, ZTS's ROE is +0.51%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, ZTS is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs RMTI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, RMTI has a market cap of 33.2M. Regarding current trading prices, ZTS is priced at $168.68, while RMTI trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas RMTI's P/E ratio is -97.07. In terms of profitability, ZTS's ROE is +0.51%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, ZTS is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs HEXO Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ZTS is priced at $168.68, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ZTS's ROE is +0.51%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ZTS is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs EGRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, EGRX has a market cap of 27.2M. Regarding current trading prices, ZTS is priced at $168.68, while EGRX trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas EGRX's P/E ratio is 2.47. In terms of profitability, ZTS's ROE is +0.51%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ZTS is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs KALA Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, KALA has a market cap of 26.9M. Regarding current trading prices, ZTS is priced at $168.68, while KALA trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas KALA's P/E ratio is -0.57. In terms of profitability, ZTS's ROE is +0.51%, compared to KALA's ROE of -3.69%. Regarding short-term risk, ZTS is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs CYTH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ZTS is priced at $168.68, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ZTS's ROE is +0.51%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, ZTS is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ZTS.
ZTS vs IXHL Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, IXHL has a market cap of 16.8M. Regarding current trading prices, ZTS is priced at $168.68, while IXHL trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas IXHL's P/E ratio is -0.15. In terms of profitability, ZTS's ROE is +0.51%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, ZTS is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs DRRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, DRRX has a market cap of 16.7M. Regarding current trading prices, ZTS is priced at $168.68, while DRRX trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas DRRX's P/E ratio is -1.12. In terms of profitability, ZTS's ROE is +0.51%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, ZTS is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs GELS Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, GELS has a market cap of 16.1M. Regarding current trading prices, ZTS is priced at $168.68, while GELS trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas GELS's P/E ratio is -7.12. In terms of profitability, ZTS's ROE is +0.51%, compared to GELS's ROE of -0.21%. Regarding short-term risk, ZTS is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs PRPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, PRPH has a market cap of 14.8M. Regarding current trading prices, ZTS is priced at $168.68, while PRPH trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas PRPH's P/E ratio is -0.16. In terms of profitability, ZTS's ROE is +0.51%, compared to PRPH's ROE of -1.59%. Regarding short-term risk, ZTS is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs ACRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ZTS is priced at $168.68, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ZTS's ROE is +0.51%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, ZTS is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs FLGC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, FLGC has a market cap of 13.9M. Regarding current trading prices, ZTS is priced at $168.68, while FLGC trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas FLGC's P/E ratio is -0.64. In terms of profitability, ZTS's ROE is +0.51%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, ZTS is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs COSM Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, COSM has a market cap of 13.1M. Regarding current trading prices, ZTS is priced at $168.68, while COSM trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas COSM's P/E ratio is -0.42. In terms of profitability, ZTS's ROE is +0.51%, compared to COSM's ROE of -0.51%. Regarding short-term risk, ZTS is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TXMD Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, TXMD has a market cap of 12.8M. Regarding current trading prices, ZTS is priced at $168.68, while TXMD trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas TXMD's P/E ratio is -5.84. In terms of profitability, ZTS's ROE is +0.51%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, ZTS is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs AGRX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ZTS is priced at $168.68, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ZTS's ROE is +0.51%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, ZTS is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs TLPH Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, TLPH has a market cap of 10M. Regarding current trading prices, ZTS is priced at $168.68, while TLPH trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas TLPH's P/E ratio is -1.11. In terms of profitability, ZTS's ROE is +0.51%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, ZTS is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs AYTU Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, AYTU has a market cap of 9.2M. Regarding current trading prices, ZTS is priced at $168.68, while AYTU trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas AYTU's P/E ratio is -1.00. In terms of profitability, ZTS's ROE is +0.51%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, ZTS is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs IMCC Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, IMCC has a market cap of 8.8M. Regarding current trading prices, ZTS is priced at $168.68, while IMCC trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas IMCC's P/E ratio is -2.07. In terms of profitability, ZTS's ROE is +0.51%, compared to IMCC's ROE of -1.52%. Regarding short-term risk, ZTS is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs YCBD Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, YCBD has a market cap of 8.7M. Regarding current trading prices, ZTS is priced at $168.68, while YCBD trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas YCBD's P/E ratio is 0.01. In terms of profitability, ZTS's ROE is +0.51%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, ZTS is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SISI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, SISI has a market cap of 8.6M. Regarding current trading prices, ZTS is priced at $168.68, while SISI trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas SISI's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.51%, compared to SISI's ROE of -1.41%. Regarding short-term risk, ZTS is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs SBFMW Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, SBFMW has a market cap of 8.6M. Regarding current trading prices, ZTS is priced at $168.68, while SBFMW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas SBFMW's P/E ratio is -0.13. In terms of profitability, ZTS's ROE is +0.51%, compared to SBFMW's ROE of -0.21%. Regarding short-term risk, ZTS is less volatile compared to SBFMW. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs NLTX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ZTS is priced at $168.68, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ZTS's ROE is +0.51%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, ZTS is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs LCI Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ZTS is priced at $168.68, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas LCI's P/E ratio is -0.04. In terms of profitability, ZTS's ROE is +0.51%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ZTS is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.
ZTS vs BGXX Comparison
ZTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 75.1B. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, ZTS is priced at $168.68, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 30.28, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ZTS's ROE is +0.51%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, ZTS is less volatile compared to BGXX. This indicates potentially lower risk in terms of short-term price fluctuations for ZTS.